26.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HROW Giù?
Forum
Previsione
Frazionamento azionario
Harrow Inc Borsa (HROW) Ultime notizie
Where Harrow Stands With Analysts - Benzinga
B. Riley Adjusts Price Target on Harrow to $65 From $69, Maintains Buy Rating - MarketScreener
Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - Yahoo Finance
Harrow Health Reports Strong 2024 Financial Performance - TipRanks
Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (NASDAQ:HROW) - Seeking Alpha
Harrow (HROW) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Harrow: Q4 Earnings Snapshot - The Advocate
Harrow Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Joplin Globe
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025 - Business Wire
Harrow Inc. sees $150k stock sale by Opaleye Management - Investing.com
Harrow sees shares increase following drug approval - Nashville Post
Craig-Hallum Reaffirms Their Buy Rating on Harrow Health (HROW) - The Globe and Mail
CMS approves separate reimbursement for Harrow’s TRIESENCE - Investing.com
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL - Business Wire
TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News - Stock Titan
Harrow Inc (HROW) Shares Up 1.14% on Mar 22 - GuruFocus
Opaleye management sells $148,200 in Harrow, Inc. stock - Investing.com India
What To Expect From Harrow Inc (HROW) Q4 2024 Earnings - GuruFocus
Opaleye Management Inc. Adjusts Stake in Harrow Inc. - GuruFocus
Bank of New York Mellon Corp Has $2.90 Million Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow Inc (HROW) Shares Up 2.97% on Mar 21 - GuruFocus
Opaleye management sells $148,200 in Harrow, Inc. stock By Investing.com - Investing.com South Africa
Harrow: A Name I Am Accumulating (NASDAQ:HROW) - Seeking Alpha
H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target By Investing.com - Investing.com Australia
H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target - Investing.com India
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial - GlobeNewswire Inc.
Harrow stock surges on preliminary Q4 numbers - Nashville Post
Sector Update: Health Care -March 18, 2025 at 08:49 am EDT - Marketscreener.com
Harrow Soars On Preliminary Q4 Results, Revenue Outlook - RTTNews
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga India
Harrow Reports Preliminary 2024 Q4 and Full-Year Financial Results, Provides 2025 Guidance and Launches New Initiative - VisionMonday.com
Harrow Inc (HROW) Reports Q4 Revenue Between $65M-$67M, Surpassi - GuruFocus.com
Harrow Completes Transfer of the TRIESENCE® New Drug Application - Business Wire
Harrow Reports Q4 Preliminary Revenue -- Shares Rise After Hours -March 17, 2025 at 04:30 pm EDT - Marketscreener.com
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance - Business Wire
Harrow Launches VEVYE® Access for All - Business Wire
Harrow Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
HARROW HEALTH Earnings Preview: Recent $HROW Insider Trading, Hedge Fund Activity, and More - Nasdaq
Harrow shares react modestly to FDA move | Area Stocks - Nashville Post
Harrow shares react modestly to FDA move - Nashville Post
Harrow shares react to FDA move - Nashville Post
Harrow Signs 5-Year Supply Deal for Triesence -March 11, 2025 at 08:36 am EDT - Marketscreener.com
Harrow Executes Five-Year Strategic Supply And Development Agreement For TRIESENCE - Marketscreener.com
Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE® - Business Wire
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):